心肌T1ρ定量成像在T1、T2定量成像基础上对接受蒽环类联合或不联合曲妥珠单抗治疗的乳腺癌患者后续癌症治疗相关心功能障碍的额外预测价值
该前瞻性研究纳入82例接受蒽环类联合或不联合曲妥珠单抗治疗的乳腺癌患者,于基线、3个月和6个月行心脏磁共振T1ρ、T1和T2定量成像。19例(23.17%)发生癌症治疗相关心功能障碍(CTRCD)。基线至3个月T1ρ变化(OR 3.892,p=0.003)和T1变化(OR 1.082,p=0.002)与后续CTRCD相关,两者联合的AUC提高至0.853;T1ρ定量成像为T1定量成像预测后续CTRCD提供了额外价值。
要点
- 基线至3个月心肌T1ρ变化与后续CTRCD相关(OR 3.892,p=0.003)。
- 基线至3个月心肌T1变化与后续CTRCD相关(OR 1.082,p=0.002)。
- T1ρ与T1变化联合预测后续CTRCD的AUC提高至0.853。
核心结论
- 心肌T1ρ定量成像为T1定量成像预测接受蒽环类联合或不联合曲妥珠单抗治疗的乳腺癌患者后续CTRCD提供了额外预测价值。
研究设计与样本
- 前瞻性研究,2021年3月至2023年5月连续纳入82例接受蒽环类联合或不联合曲妥珠单抗治疗的乳腺癌患者,于基线、3个月和6个月行心脏磁共振T1ρ、T1和T2定量成像。
关键影像表现/征象
- CTRCD阳性组和CTRCD阴性组T1ρ和T1值均随时间逐渐升高(均p<0.001)。
- CTRCD阳性组和CTRCD阴性组T2值在3个月(分别为p<0.001和p=0.002)和6个月(均p<0.001)较基线升高。
诊断标准与关键数值
- 基线至3个月T1ρ变化预测后续CTRCD的OR为3.892(p=0.003)。
- 基线至3个月T1变化预测后续CTRCD的OR为1.082(p=0.002)。
- 基线至3个月T1ρ变化与T1变化联合预测后续CTRCD的AUC为0.853。
临床应用与阅片要点
- 在乳腺癌患者蒽环类联合或不联合曲妥珠单抗治疗过程中,可于基线及3个月行心肌T1ρ和T1定量成像评估其变化以预测后续CTRCD。
- T1ρ定量成像可补充T1定量成像,提高对后续CTRCD的预测效能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: We aimed to describe changes in parameters derived from myocardial T1ρ, T1, and T2 mapping and assess whether incorporating T1ρ mapping improves the predictive performance of T1 and T2 mapping for subsequent cancer therapy-related cardiac dysfunction (CTRCD) in breast cancer patients treated with anthracyclines with/without trastuzumab.
METHODS: From March 2021 to May 2023, 82 participants with breast cancer treated with anthracyclines with/without trastuzumab were prospectively recruited. Cardiac magnetic resonance was performed at baseline, 3 and 6 months in relation to baseline. T1ρ, T1 and T2 values were measured and compared by repeated measures analyses of variance. Logistic regression and receiver operating characteristic analysis were used to assess the performance in predicting subsequent CTRCD.
RESULTS: Nineteen (23.17 %) participants developed CTRCD. T1ρ and T1 values progressively increased over time (all p < 0.001), while T2 values increased at 3 (p < 0.001 and p = 0.002, respectively) and 6 months (all p < 0.001) compared to baseline in both the CTRCD (+) and CTRCD (-) groups. The changes in T1ρ (OR, 3.892, p = 0.003) and T1 (OR, 1.082, p = 0.002) from baseline to 3 months were associated with subsequent CTRCD. The combination of the changes in T1ρ and T1 from baseline to 3 months obtained an improved area under the curve of 0.853.
CONCLUSION: T1ρ, T1 and T2 increased after treatment of anthracyclines with/without trastuzumab. Myocardial T1ρ mapping provides additional predictive value to T1 mapping for subsequent CTRCD in breast cancer patients who received anthracyclines with/without trastuzumab.
CLINICAL RELEVANCE STATEMENT: Myocardial T1ρ mapping offers additional predictive value to T1 and T2 mapping for subsequent CTRCD in breast cancer patients who received anthracyclines with/without trastuzumab. This may facilitate accurate prediction of cardiotoxicity and personalized treatment decision making in breast cancer.
引用
- Li X, Shen H, Peng Y, et al. The additional value of myocardial T1ρ mapping to T1 and T2 mapping for predicting subsequent cancer therapy-related cardiac dysfunction in breast cancer patients who received anthracyclines with/without trastuzumab. Eur J Radiol. 2024. PMID: 39342884. doi:10.1016/j.ejrad.2024.111755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。